- Home
- TEI vs AVIR Comparison
TEI vs AVIR Comparison
Compare TEI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- AVIR
- Stock Information
- Founded
- TEI 1993
- AVIR 2012
- Country
- TEI United States
- AVIR United States
- Employees
- TEI N/A
- AVIR N/A
- Industry
- TEI Finance Companies
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- TEI Finance
- AVIR Health Care
- Exchange
- TEI Nasdaq
- AVIR Nasdaq
- Market Cap
- TEI 282.9M
- AVIR 277.8M
- IPO Year
- TEI N/A
- AVIR 2020
- Fundamental
- Price
- TEI $6.07
- AVIR $3.50
- Analyst Decision
- TEI
- AVIR Hold
- Analyst Count
- TEI 0
- AVIR 1
- Target Price
- TEI N/A
- AVIR $6.00
- AVG Volume (30 Days)
- TEI 142.4K
- AVIR 355.9K
- Earning Date
- TEI 01-01-0001
- AVIR 08-07-2025
- Dividend Yield
- TEI 10.51%
- AVIR N/A
- EPS Growth
- TEI N/A
- AVIR N/A
- EPS
- TEI N/A
- AVIR N/A
- Revenue
- TEI N/A
- AVIR N/A
- Revenue This Year
- TEI N/A
- AVIR N/A
- Revenue Next Year
- TEI N/A
- AVIR N/A
- P/E Ratio
- TEI N/A
- AVIR N/A
- Revenue Growth
- TEI N/A
- AVIR N/A
- 52 Week Low
- TEI $4.35
- AVIR $2.46
- 52 Week High
- TEI $5.39
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- TEI 58.45
- AVIR 48.71
- Support Level
- TEI $6.05
- AVIR $3.33
- Resistance Level
- TEI $6.13
- AVIR $3.60
- Average True Range (ATR)
- TEI 0.05
- AVIR 0.16
- MACD
- TEI 0.00
- AVIR -0.02
- Stochastic Oscillator
- TEI 75.00
- AVIR 26.69
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).